9月15日，美年健康盘中下跌2.09%，截至13:17，报5.15元/股，成交2.54亿元，换手率1.26%，总市值 201.58亿元。 美年健康所属申万行业为：医药生物-医疗服务-医院。所属概念板块包括：互联医疗、AIAgent（智能 体）、家庭医生概念、数据要素、智慧医疗等。 截至6月30日，美年健康股东户数17.24万，较上期减少8.95%；人均流通股22471股，较上期增加 9.87%。2025年1月-6月，美年健康实现营业收入41.09亿元，同比减少2.28%；归母净利润-2.21亿元，同 比减少2.59%。 分红方面，美年健康A股上市后累计派现6.34亿元。近三年，累计派现1.27亿元。 机构持仓方面，截止2025年6月30日，美年健康十大流通股东中，华宝中证医疗ETF（512170）位居第 七大流通股东，持股1.04亿股，相比上期增加190.34万股。招商优势企业混合A（217021）位居第十大 流通股东，持股6000.00万股，为新进股东。香港中央结算有限公司退出十大流通股东之列。 责任编辑：小浪快报 资金流向方面，主力资金净流出3226.20万元，特大单买入1013.28万元，占比4.00% ...

Company Overview - Tiger Med is a clinical research service provider based in Hangzhou, China, specializing in I-IV phase clinical trials, data management, and medical testing services [1][2] - The company was established on December 15, 2004, and went public on August 17, 2012 [1] Financial Performance - For the first half of 2025, Tiger Med reported a revenue of 3.25 billion yuan, a year-on-year decrease of 3.21%, and a net profit attributable to shareholders of 383 million yuan, down 22.22% year-on-year [2] - The company has distributed a total of 2.46 billion yuan in dividends since its A-share listing, with 1.15 billion yuan distributed over the last three years [3] Stock Performance - As of September 15, Tiger Med's stock price increased by 2.02% to 62.24 yuan per share, with a market capitalization of 53.59 billion yuan [1] - Year-to-date, the stock has risen by 14.58%, but it has seen a decline of 7.37% over the last five trading days and 10.45% over the last 20 days [1] Shareholder Structure - As of June 30, 2025, Tiger Med had 51,500 shareholders, a decrease of 4.14% from the previous period [2] - The top shareholders include various funds, with notable changes in holdings among major institutional investors [3]

Core Viewpoint - Oriental国信's stock price has shown volatility with a year-to-date increase of 20.11%, but recent performance indicates mixed trends, including a 6.69% decline over the past 20 days [1][2]. Financial Performance - For the first half of 2025, Oriental国信 reported revenue of 941 million yuan, a year-on-year decrease of 8.37%, and a net profit attributable to shareholders of -79.17 million yuan, a significant decline of 625.60% [2]. - The company has not distributed any dividends in the past three years, with a total payout of 156 million yuan since its A-share listing [3]. Shareholder Structure - As of June 30, 2025, the number of shareholders decreased by 4.37% to 85,700, while the average circulating shares per person increased by 4.57% to 10,573 shares [2]. - The top ten circulating shareholders include Hong Kong Central Clearing Limited and various ETFs, with notable increases in holdings for some [3]. Market Activity - On September 12, 2023, Oriental国信's stock price rose by 2.08% to 11.29 yuan per share, with a trading volume of 98.78 million yuan and a turnover rate of 0.98% [1]. - The stock has appeared on the龙虎榜 twice this year, with the most recent net purchase of 154 million yuan on August 6, 2023 [1]. Business Overview - Oriental国信, established on July 28, 1997, and listed on January 25, 2011, specializes in enterprise-level big data and cloud computing products, industrial internet platforms, and overall industry solutions [2]. - The revenue composition includes 76.59% from custom software development and services, 16.14% from system integration, 5.60% from cloud computing, and 1.68% from software products [2].

Core Viewpoint - The stock of Haishike has shown significant performance with a year-to-date increase of 76.74%, despite a recent decline over the past 20 days [1][2]. Group 1: Stock Performance - As of September 11, Haishike's stock price reached 58.29 CNY per share, with a market capitalization of 65.28 billion CNY [1]. - The stock has experienced a 1.78% increase over the last five trading days and a 37.93% increase over the last 60 days [1]. - The company has seen a net outflow of 4.30 million CNY in principal funds, with large orders showing a buy of 14.74 million CNY and a sell of 19.74 million CNY [1]. Group 2: Financial Performance - For the first half of 2025, Haishike reported a revenue of 2.00 billion CNY, reflecting an 18.63% year-on-year growth, while the net profit attributable to shareholders decreased by 21.79% to 129 million CNY [2]. - Cumulatively, the company has distributed 3.67 billion CNY in dividends since its A-share listing, with 687 million CNY distributed over the past three years [3]. Group 3: Shareholder Information - As of June 30, 2025, the number of shareholders increased by 25.93% to 11,400, with an average of 42,147 circulating shares per person, down by 28.64% [2]. - The top ten circulating shareholders include several mutual funds, with notable increases in holdings from institutions such as China Europe Medical Health Mixed A and ICBC Frontier Medical Stock A [3].

Group 1 - The core viewpoint of the news highlights the recent performance and financial metrics of Wanma Technology, including stock price movements and trading volumes [1][2] - As of September 11, Wanma Technology's stock price increased by 2.10% to 46.20 CNY per share, with a total market capitalization of 6.191 billion CNY [1] - The company has seen a year-to-date stock price increase of 34.07%, with a 7.14% rise over the last five trading days [1] Group 2 - Wanma Technology's main business segments include vehicle networking (46.44%), cabinet and chassis products (30.39%), industrial control products (11.64%), other products (6.64%), and medical information products (4.89%) [1] - For the first half of 2025, Wanma Technology reported a revenue of 339 million CNY, representing a year-on-year growth of 50.91%, and a net profit attributable to shareholders of 16.464 million CNY, up 3.06% [2] - The company has distributed a total of 35.242 million CNY in dividends since its A-share listing, with 30.82 million CNY distributed over the past three years [2]

Core Viewpoint - YXTT's stock price has shown fluctuations in recent trading sessions, with a year-to-date increase of 16.53% but a recent decline of 1.00% over the last five trading days [2] Group 1: Stock Performance - As of September 11, YXTT's stock price was 14.83 CNY per share, with a market capitalization of 8.685 billion CNY [1] - The stock has experienced a 2.05% decline during the trading session on September 11, with a trading volume of 41.0343 million CNY and a turnover rate of 0.69% [1] - Year-to-date, YXTT has appeared on the "Dragon and Tiger List" twice, with the most recent appearance on May 23, where it recorded a net buy of -4.0951 million CNY [2] Group 2: Financial Performance - For the first half of 2025, YXTT reported a revenue of 8.914 billion CNY, a year-on-year decrease of 4.20%, and a net profit attributable to shareholders of 250 million CNY, down 11.44% year-on-year [2] - Cumulative cash dividends since YXTT's A-share listing amount to 1.908 billion CNY, with 649 million CNY distributed over the past three years [3] Group 3: Shareholder Structure - As of June 30, 2025, YXTT had 33,900 shareholders, a decrease of 5.42% from the previous period, with an average of 11,712 circulating shares per shareholder, an increase of 5.73% [2] - The top ten circulating shareholders include Hong Kong Central Clearing Limited, which holds 18.5744 million shares, a decrease of 21.1993 million shares from the previous period [3] - New entrants among the top ten shareholders include several funds, such as Guangfa Technology Innovation Mixed Fund and Invesco Great Wall Growth Star Stock A [3]

Core Viewpoint - Ji'an Medical's stock price has shown fluctuations, with a slight increase of 2.02% on September 8, 2023, while the company faces a decline in revenue but an increase in net profit year-on-year [1][2]. Company Overview - Ji'an Medical, established on August 22, 1995, and listed on June 10, 2010, is located in Tianjin and specializes in the research, production, and sales of home medical health electronic products [1]. - The company operates within the pharmaceutical and biological industry, specifically in medical devices and in vitro diagnostics [1]. Financial Performance - For the first half of 2025, Ji'an Medical reported a revenue of 765 million yuan, a year-on-year decrease of 43.35%, while the net profit attributable to shareholders reached 920 million yuan, reflecting a year-on-year increase of 52.91% [2]. - Cumulatively, the company has distributed 1.794 billion yuan in dividends since its A-share listing, with 1.39 billion yuan distributed over the past three years [3]. Shareholder Information - As of August 10, 2025, the number of Ji'an Medical shareholders increased to 73,000, with an average of 6,491 circulating shares per person, a decrease of 2.19% from the previous period [2]. - The top ten circulating shareholders include notable ETFs, with the Huabao Zhongzheng Medical ETF holding 10.9885 million shares, a decrease of 1.836 million shares from the previous period [3].

Core Viewpoint - The company, Yimikang Technology Group Co., Ltd., has shown significant growth in revenue and net profit in the first half of 2025, indicating strong operational performance and market demand for its services in the digital infrastructure sector [2]. Group 1: Stock Performance - On September 5, Yimikang's stock price increased by 2.01%, reaching 16.24 CNY per share, with a trading volume of 1.60 billion CNY and a turnover rate of 2.68%, resulting in a total market capitalization of 71.54 billion CNY [1]. - Year-to-date, Yimikang's stock price has risen by 27.07%, but it has experienced a decline of 11.11% over the last five trading days and a decrease of 4.02% over the last 20 days [1]. - The company has appeared on the "Dragon and Tiger List" three times this year, with the most recent appearance on February 14, where it recorded a net purchase of 51.66 million CNY [1]. Group 2: Company Overview - Yimikang, established on September 12, 2002, and listed on August 3, 2011, is based in Chengdu, Sichuan Province, and specializes in providing green solutions for the entire lifecycle of digital infrastructure [2]. - The company's main business revenue is derived entirely from ICT products, and it operates across four key segments: critical equipment, smart engineering, IoT software, and intelligent services [2]. - As of June 30, the number of shareholders decreased by 8.79% to 59,700, while the average circulating shares per person increased by 9.59% to 6,249 shares [2]. Group 3: Financial Performance - For the first half of 2025, Yimikang reported a revenue of 737 million CNY, representing a year-on-year growth of 54.82%, and a net profit attributable to shareholders of 14.92 million CNY, which is a 124.13% increase compared to the previous year [2].

Core Viewpoint - The stock of China Electric Port has shown fluctuations in trading performance, with a recent increase of 2.00% and a total market capitalization of 15.479 billion yuan as of September 5 [1] Group 1: Stock Performance - As of September 5, the stock price of China Electric Port is 20.37 yuan per share, with a trading volume of 142 million yuan and a turnover rate of 1.61% [1] - Year-to-date, the stock price has increased by 0.85%, but it has decreased by 9.39% over the last five trading days [1] - The stock has appeared on the "Dragon and Tiger List" four times this year, with the most recent appearance on July 21, where it recorded a net buy of -86.0912 million yuan [1] Group 2: Company Overview - China Electric Port, established on September 28, 2014, is located in Shenzhen, Guangdong Province, and was listed on April 10, 2023 [2] - The company primarily engages in electronic component distribution, accounting for 99.89% of its revenue, with other services making up the remaining 0.11% [2] - The company operates in the electronic industry, specifically in the sub-sectors of other electronics [2] Group 3: Financial Performance - For the first half of 2025, China Electric Port reported a revenue of 33.526 billion yuan, representing a year-on-year growth of 35.64%, and a net profit attributable to shareholders of 181 million yuan, up 64.98% [2] - Since its A-share listing, the company has distributed a total of 258 million yuan in dividends [3] Group 4: Shareholder Information - As of June 30, 2025, the number of shareholders for China Electric Port is 76,700, a decrease of 10.72% from the previous period [2] - The top ten circulating shareholders include various ETFs, with notable increases in holdings from Southern CSI 1000 ETF and others [3]

Company Overview - Haisco Pharmaceutical Group Co., Ltd. is located in Zedang Town, Shannan City, Tibet, and was established on August 26, 2005. The company was listed on January 17, 2012. Its main business involves the research, development, production, and sales of chemical pharmaceuticals. The revenue composition is 99.14% from the pharmaceutical industry and 0.86% from other sources [1]. Stock Performance - As of September 5, Haisco's stock price decreased by 2.04%, trading at 56.10 CNY per share, with a total market capitalization of 62.827 billion CNY. The stock has increased by 70.10% year-to-date, with a 1.15% increase over the last five trading days, a 5.65% decrease over the last 20 days, and a 20.78% increase over the last 60 days [1]. Financial Performance - For the first half of 2025, Haisco reported a revenue of 2.001 billion CNY, representing a year-on-year growth of 18.63%. However, the net profit attributable to shareholders decreased by 21.79% to 129 million CNY [2]. Shareholder Information - As of June 30, 2025, Haisco had 11,400 shareholders, an increase of 25.93% from the previous period. The average number of tradable shares per shareholder decreased by 28.64% to 42,147 shares [2]. Dividend Distribution - Haisco has distributed a total of 3.673 billion CNY in dividends since its A-share listing, with 687 million CNY distributed over the past three years [3]. Institutional Holdings - As of June 30, 2025, among the top ten circulating shareholders, several funds increased their holdings, including China Europe Medical Health Mixed A, which holds 21.2763 million shares, an increase of 5.3574 million shares. Other funds also saw increases, while one fund reduced its holdings [3].